Literature DB >> 6356278

The antimicrobial activity of rifampin: emphasis on the relation to phagocytes.

G L Mandell.   

Abstract

Rifampin appears to be a uniquely effective antibiotic for the treatment of certain infections. Only rifampin, of nine antimicrobial agents studied, killed staphylococci inside polymorphonuclear neutrophils or Escherichia coli inside macrophages. Rifampin, unlike penicillin, penetrated living, intact neutrophils. Rifampin was more effective than other antistaphylococcal antibiotics for the treatment of staphylococcal infections induced by subcutaneous, intraperitoneal, or intravenous injection of the organisms into mice. Rifampin-resistant variants occur in low numbers among clinical isolates (frequency, 10(-8)), and some of these variants are diminished in virulence for mice. Treatment of infected mice with rifampin plus another antimicrobial agent prevented the emergence of resistant variants. Thus, there is firm in vitro and in vivo support for studies of the clinical efficacy of rifampin for staphylococcal infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356278     DOI: 10.1093/clinids/5.supplement_3.s463

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  14 in total

1.  Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.

Authors:  M H Chandler; S M Toler; R P Rapp; R R Muder; J A Korvick
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

2.  Chronic osteomyelitis.

Authors:  Ilker Uçkay; Kheeldass Jugun; Axel Gamulin; Joe Wagener; Pierre Hoffmeyer; Daniel Lew
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

3.  Uptake, intracellular activity, and influence of rifampin on normal function of polymorphonuclear leukocytes.

Authors:  P H Höger; K Vosbeck; R Seger; W H Hitzig
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity.

Authors:  W L Hand; N L King-Thompson
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

5.  Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants.

Authors:  M Drancourt; A Stein; J N Argenson; A Zannier; G Curvale; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits.

Authors:  S L Barriere; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.

Authors:  P Van der Auwera; J Klastersky; J P Thys; F Meunier-Carpentier; J C Legrand
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

8.  Efficacies of various antimicrobial agents in treatment of Staphylococcus aureus abscesses and correlation with in vitro tests of antimicrobial activity and neutrophil killing.

Authors:  D M Bamberger; M T Fields; B L Herndon
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  Antibiotics and prevention of microbial colonization of catheters.

Authors:  I Raad; R Darouiche; R Hachem; M Sacilowski; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Influence of rifampin on fleroxacin pharmacokinetics.

Authors:  J Schrenzel; P Dayer; T Leemann; E Weidekamm; R Portmann; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.